New Treatments for a Common Pediatric Brain Tumor

by Anjali Aryamvally on  April 1, 2018 at 12:44 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

New study details the mechanisms underlying development of a common pediatric brain tumor called medulloblastoma. These findings could lead to new treatments for the condition.
New Treatments for a Common Pediatric Brain Tumor
New Treatments for a Common Pediatric Brain Tumor

Show Full Article


Medulloblastomas originate in the cerebellum, an area at the skull's base that regulates motor control, posture, and balance. The Sonic Hedgehog subtype of medulloblastoma occurs when too many of a particular brain cell type -- granule cells -- are made. Granule cells make up most of the cerebellum and constitute as much as 80 percent of all brain neurons. During normal development, many granule cells are made when other nearby cells release the protein Sonic Hedgehog. However, some granule cells are made in the cerebellum even before Sonic Hedgehog is released, which led the researchers to investigate other factors that regulate early granule cell production.

"We modeled the Sonic Hedgehog medulloblastoma in mice by deleting a gene for a G protein-coupled receptor called Gpr161 that was not known to be involved in this tumor," said first author Dr. Issei Shimada, Assistant Instructor in Cell Biology. "Interestingly, we found that in the absence of Gpr161, which actively represses the downstream pathway, the granule cells proliferate even before Sonic Hedgehog is secreted."

Dr. Mukhopadhyay added, "Repression of the downstream pathway in the absence of Sonic Hedgehog is as important as activation in its presence. Bottom line: The granule cell behaves like a car on a downhill slope with the hand brake on. Loss of the hand brake is as damaging as the accelerator being pressed too hard."

This means that Gpr161 acts as a tumor suppressor for Sonic Hedgehog medulloblastomas by preventing too many granule cells from being made.

Medulloblastomas account for 15 to 20 percent of all pediatric brain tumors, according to the National Institutes of Health. While they are most commonly diagnosed in children between ages 3 and 8, they can be seen in all age groups. About 350 cases are diagnosed each year in the U.S.

In 2017, a survey of the National Cancer Database tracked 4,032 patients with medulloblastomas. Of these, 1,300 were age 18 or younger and received chemotherapy and radiation treatment. The median age was 8.4 years, and the group's five-year survival rate was 79 percent.

Only one drug, vismodegib, currently targets the upstream Sonic Hedgehog pathway for treating these pediatric tumors, Dr. Mukhopadhyay said. Now that this work has identified Gpr161 as a tumor suppressor, focusing on Gpr161 might be a new strategy to inhibit progression of tumors that develop resistance to drugs targeting the upstream Sonic Hedgehog pathway, he said.



Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

In April of last year, i started on natural parkinsons disease herbal treatments from RICH HERBS FOUNDATION, i am happy to report this PD herbal treatment worked very effectively. My parkinson is totally under control, i had a total decline in symptoms, the tremors, shaking, stiffness, congnition and speech problems stopped. Visit rich herbs foundation official web page w w w. richherbsfoundation. c o m. My family are amazed at the change and rapid recovery from pd.

Recommended Reading

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

News Category

News Archive